Compare MSC & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSC | HQL |
|---|---|---|
| Founded | 2000 | 1992 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Investment Managers |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.4M | 496.4M |
| IPO Year | 2017 | N/A |
| Metric | MSC | HQL |
|---|---|---|
| Price | $2.92 | $16.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 728.0 | ★ 122.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $21.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $10.55 |
| 52 Week High | $6.63 | $17.80 |
| Indicator | MSC | HQL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.64 |
| Support Level | N/A | $16.40 |
| Resistance Level | N/A | $17.45 |
| Average True Range (ATR) | 0.00 | 0.26 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 23.71 |
Studio City International Holdings Ltd is a gaming, retail, and entertainment resort located in Cotai, Macau. It operates Studio City Casino with around 250 mass-market gaming tables; including tables for VIP rolling chip operations, and 552 gaming machines. Studio City features luxury hotel rooms, diverse food and beverage establishments, and complementary retail space. In addition, the company offers non-gaming attractions, including the world's first figure-8 Ferris wheel, a deluxe nightclub and karaoke venue, a live performance arena, an outdoor and an indoor water park. Geographically, the company derives the majority of its revenue from the Macau region.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.